Jim Simons Inhibikase Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.54 - $0.91 $8,262 - $13,923	15,300 Added 29.42%	67,300 $44,000
Q4 2022 Feb 13, 2023	SELL	$0.45 - $5.41 $32,707 - $393,215	-72,683 Reduced 58.29%	52,000 $26,000
Q3 2022 Nov 14, 2022	SELL	$0.76 - $5.46 $73,884 - $530,804	-97,217 Reduced 43.81%	124,683 $113,000
Q2 2022 Aug 12, 2022	BUY	$0.63 - $1.44 $21,061 - $48,140	33,431 Added 17.74%	221,900 $165,000
Q1 2022 May 13, 2022	SELL	$1.03 - $1.77 $13,112 - $22,533	-12,731 Reduced 6.33%	188,469 $279,000
Q4 2021 Feb 11, 2022	BUY	$1.38 - $2.17 $277,656 - $436,604	201,200 New	201,200 $296,000

1.03M

Ticker IKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,227,100
Market Cap $32.8M
Description
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.